Sunday, 19 May 2024


Alcon shares target raised by Baird on growth prospects By

Baytex Reports Shareholder Meeting Results By

On Wednesday, Baird, a financial services firm, increased its price target for Alcon Inc. (NYSE: NYSE:) shares to $104, up from the previous $95. The firm has also reiterated its Outperform rating on the stock.

The adjustment follows Alcon’s robust performance in the first quarter of 2024, which highlighted the company’s dominance in various fast-growing markets.

Alcon’s recent financial results have demonstrated significant growth, particularly in the contact lens segment, which is expected to continue driving the company’s revenue and margins throughout 2024.

Baird anticipates that Alcon’s surgical products will contribute to the company’s growth in 2025. This outlook supports Baird’s positive stance on Alcon’s prospects over multiple years.

Despite a 9% increase in Alcon’s share price on Wednesday, when the S&P 500 index remained unchanged, Baird believes there is still potential for further appreciation.

Alcon’s shares are currently trading at approximately 17 times next twelve months’ (NTM) EBITDA, which is lower compared to its peers in the high-quality, fast-growing, large-cap medical technology sector, such as Stryker (NYSE:), Boston Scientific (NYSE:), and Edwards Lifesciences (NYSE:), which trade between 21 and 23 times NTM EBITDA.

The financial firm’s analysis indicates that Alcon’s market position and growth trajectory make it a top pick within their coverage universe.

The revised price target reflects confidence in Alcon’s continued market leadership and its ability to capitalize on opportunities within the medical technology industry.

InvestingPro Insights

Following Baird’s update on Alcon Inc. (NYSE: ALC), InvestingPro data further enriches the outlook on the company. Alcon’s market capitalization stands at a robust $43.66 billion, reflecting its significant presence in the industry. With a P/E ratio of 38.82 and a slight increase to 41.78 over the last twelve months as of Q1 2024, the company’s valuation is on the higher side, which aligns with Baird’s optimistic view. However, the PEG ratio of 0.2 for the same period suggests that Alcon’s earnings growth could be undervalued relative to its peers, potentially offering an attractive entry point for investors.

3rd party Ad. Not an offer or recommendation by See disclosure here or
remove ads

InvestingPro Tips provide additional insights. Alcon has demonstrated a strong return over the last week with an 11.35% price total return, and it continues to trade near its 52-week…

Click Here to Read the Full Original Article at All News…